Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
Chinese stocks sell off amid fears of a new SARS during the biggest migration of people on the planet.
IBM reports its Q4 results after today's market close and is my 2020 pick for the year.
There is nothing in small-caps to suggest that they are as frothy as the big-caps.
I think we'll see that the choice between Netflix, Disney +, and Apple TV + isn't a zero-sum game.